The Tau Consortium, funded by the Rainwater Charitable Foundation, is a highly collaborative international group of scientists and clinicians united to develop new treatments for Alzheimer’s disease, frontotemporal dementia, and other neurodegenerative diseases involving tau protein dysfunction.
The Tau Consortium Stem Cell Group includes investigators from NSCI, University of California, Harvard University, Washington University, and Mount Sinai New York, who are using “disease in a dish” models to study disease mechanisms and identify therapeutic agents. One key resource from this work is a world-class collection of induced pluripotent stem cells (iPSCs) generated from skin biopsies donated by patients carrying mutations linked to tauopathies or by healthy individuals. Many iPSC lines have been further developed into isogenic pairs via CRISPR editing. Collections are available to for-profit and non-profit organizations. Please use the links below for cell line information:
For fibroblast requests please contact Aimee Kao (Aimee.Kao@ucsf.edu) directly.
All stem cell line requests will be reviewed by the Tau Consortium’s Stem Cell Group. Request turnaround time for iPSCs is 10 business days, barring any delays from MTA execution, communication with PIs, and special requests that require an additional scope of work. Contact us for pricing information. Please submit email the following documents to the Neuracell team (firstname.lastname@example.org).
- Signed Request Form [Download Form]
- One page research summary
Upon approval, required material transfer agreements (MTA) must be signed prior to distribution.
Further information on Tau Consortium iPSC line collection can be found in the following publication: